Amador Bioscience Announces the Completion of $60 Million Series B+ Round Financing
Summary
As more first-in-class pharmaceutical projects launch in China, Amador Biosciences unique technical capabilities lead to substantial increase in its client base and market potential. We trust Dr. Bing Wang and his leadership team will take full advantage of this acquisition, continue to build up the company and its business, and become a model of globalization of Chinese CROs. "Amador Bioscience, a leading partner for successful new drug development, provides global-standard translational sciences and clinical pharmacology services to clients ranging from cutting-edge biotech start-ups to multinational pharmaceutical companies. Founded in 2018 and supported by prominent institutional investors, Amador Bioscience operates in multiple sites, which include Pleasanton, CA, Ann Arbor, MI, Germantown, MD, Richmond, VA, Hangzhou and Shanghai, China, and Limburg, Belgium. For more information, visit www.amadorbioscience.com and www.a2pg.com.MSA Capital is a China-based private equity firm with a global perspective, focusing on early and growth stage investments in key areas including healthcare, cutting-edge technology, internet, and consumption.